In the context of OUD treatment, where patient retention directly correlates with recurring revenue, this improvement could substantially impact Indivior's market performance. The study's large sample size (729 participants) and the high percentage of fentanyl-positive patients (77.5%) demonstrates robust real-world applicability. The expansion to multiple injection sites (abdomen, thigh, buttock, and upper arm) enhances treatment flexibility and could drive adoption across diverse healthcare settings, potentially expanding SUBLOCADE's addressable market. This operational advantage could accelerate market penetration in both specialized addiction treatment centers and general medical practices. From a competitive standpoint, these label changes create significant barriers to entry for competitors, as replicating such comprehensive clinical data would require substantial time and investment.